With Biotene Acquisition, Glaxo Tries Again In Dry-Mouth Category
This article was originally published in The Rose Sheet
Executive Summary
GlaxoSmithKline expands its consumer oral-care business with the acquisition of Laclede's Biotene line of products indicated for dry mouth, or xerostomia
You may also be interested in...
Biotene OTC Dry Mouth Competitor Remains On Market As GSK Litigates
Former Biotene owner Laclede ordered by US federal judge to stop using brand, now owned by GSK, to promote its competing line of Salivea dry mouth products. But judge rejected GSK’s request that the Salivea dry mouth product marketers are subject to a lifetime non-compete agreement.
Biotene OTC Dry Mouth Competitor Remains On Market As GSK Litigates
Former Biotene owner Laclede ordered by federal judge to stop using brand, now owned by GSK, to promote its competing line of Salivea dry mouth products. But judge rejected GSK’s request that the Salivea dry mouth product marketers are subject to a lifetime non-compete agreement.
GSK Consumer Unit Finds Growth Groove By Innovating, Acquiring, Expanding
GlaxoSmithKline's consumer health-care business increased its sales by 8 percent in the firm's latest earnings period, reflecting the firm's "strategy to grow and diversify the business away from a dependency on 'white pill/western markets,'" CEO Andrew Witty noted